AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02028286
Drug: CLS001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01844726
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of placebo (saline)
Trial: NCT03771157
Drug: Shingrix vaccine
RxNorm normalized name: SHINGRIX vaccine 0.5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On day one, patients will receive the first of two doses of the Shingrix vaccine administered as an injection into the muscle in their upper arm. The second dose of vaccine will be administered as an injection to their upper arm approximately 2 months after the first dose.
Trial: NCT02089581
Drug: MRXXX
RxNorm normalized name: I'm afraid I don't have enough information to determine the full generic name for the drug abbreviation 'MRXXX'. Drug abbreviations can vary and may not be standardized, so without more context about the specific drug or clinical trial, I cannot provide the full generic name. If you have additional details about the drug or trial, please provide that information, and I'll do my best to look up the full generic name.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRXXX
Trial: NCT02089581
Drug: MR1XXX
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03119610
Drug: Placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)
Trial: NCT04004572
Drug: LEAP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given LEAP regimen every 3 weeks for 8 cycles.
Trial: NCT01784614
Drug: LY2624803 - Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as reconstituted solution
Trial: NCT03502577
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03502577
Drug: Gamma-Secretase Inhibitor LY3039478
RxNorm normalized name: .GAMMA.-OCTALACTONE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01851707
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.
Trial: NCT01784614
Drug: LY2624803 - Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as a capsule
Trial: NCT01784614
Drug: Placebo - Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as solution
Trial: NCT01784614
Drug: Placebo - Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as a capsule
Trial: NCT01484561
Drug: CP-690,550 or Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-690,550 10 mg twice a day (BID) orally or placebo BID orally, approximately 72 days
Trial: NCT01484561
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID orally, approximately 72 days
Trial: NCT00520845
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 mg will be taken by mouth twice a day for 6 weeks then 400 mg twice a day for up to a year after chemotherapy is discontinued in the absence of progression.
Trial: NCT00220454
Drug: Hydrocortone
RxNorm normalized name: Hydrocortone
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00387959
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01015677
Drug: MK-6913
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01015677
Drug: 17-β estradiol
RxNorm normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01015677
Drug: Placebo to MK-6913
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01015677
Drug: Placebo to 17-β estradiol
RxNorm normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01015677
Drug: MK-6913 25 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04114240
Drug: Xybilun
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erectil dysfunction, Viagra generic (sildénafil)
Trial: NCT02551744
Drug: proton pump inhibitor group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pantoprazole tab 40 mg qd for 6 months.
Trial: NCT00872001
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline, 500 mL delivered as an IV infusion over approximately 7 hours commencing within approximately 30 minutes before induction of anesthesia at a rate of 1.2 mL/min for a 500 mL solution. In addition, standard cardioplegia solution with added normal saline will be administered, and placebo (normal saline) will also be added to the heart lung machine priming solution.
Trial: NCT00258440
Drug: Weekly procrit dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose is standard of care, the investigational piece is the dosing schedule itself. Either weekly or Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week.
Trial: NCT02761460
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-rhG-CSF 6mg is given for patients Greater than or equal to 45 kg, 3mg is given for those less than 45kg 24-48 hours after chemotherapy
Trial: NCT00562978
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00994786
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo starting at 75 mg/day (at Study Week 0). Doses will be titrated up in 75 mg increments until a clinical response is achieved, as tolerated in the following manner: to 150 mg/day at the end of Study Week 1, to 225 mg/day at the end of Study Week 2, 300 mg/day at the end of Study Week 4, 450 mg/day at the end of Study Week 6 and to 600 mg/day at the end of Study Week 8. The maximum dose of pregabalin/placebo will be 600 mg/day.
Trial: NCT01058434
Drug: TKI258
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00366301
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 4 pills per day
Trial: NCT02238197
Drug: Atrovent® Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03184090
Drug: Endocrine therapy (non IMP)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole). Endocrine therapy must be different from previous treatment line.
Trial: NCT01660256
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00637468
Drug: Intravenous injection of heparin
RxNorm normalized name: heparin Injection
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00637468
Drug: Topical use of beta-blocker
RxNorm normalized name: Beta-HC Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00637468
Drug: Isovolaemic haemodilution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00637468
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04091360
Drug: Part A: RPL554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose RPL554 via metered dose inhaler.
Trial: NCT04091360
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: Single dose placebo via metered dose inhaler. Part B: Repeat doses of placebo via metered dose inhaler in crossover fashion. One dose administered twice daily over 7 days.
Trial: NCT04091360
Drug: Part B: RPL554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B: Repeat doses via metered dose inhaler in crossover fashion. One dose administered twice daily over 7 days.
Trial: NCT01150461
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo b.i.d.
Trial: NCT02706951
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capsule; Oral
Trial: NCT00511186
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo is administered intravenously over 48 hours. An initial loading dose of over 10-minutes is followed by continuous infusion over 48h.
Trial: NCT04477993
Drug: Janus Kinase Inhibitor (ruxolitinib)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg P.O. b.i.d. for 14 days. Dose reduction will occur if neutrophils \< 500/mm3 or platelets \<50,000/mm3.
Trial: NCT01336205
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed by the investigator
Trial: NCT02632812
Drug: Placebo effervescent granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo effervescent granules (oral), twice daily for 7 days
Trial: NCT02632812
Drug: Naproxen tablet
RxNorm normalized name: Naproxen Tablets
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen tablet 550mg (tablet), twice daily for 7 days
Trial: NCT02757313
Drug: Placebo marijuana
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00909532
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet given orally q12h for up to 48 weeks
Trial: NCT03874936
Drug: Saline Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administrated i.v.
Trial: NCT03327831
Drug: Aminolevulinic Acid
RxNorm normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical application followed by activation by ambient sunlight
Trial: NCT00571896
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill: The participants will use the placebo pills in the following manner: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 \& 3 (2 tabs at night and in the morning) until the first-postoperative visit.
Trial: NCT01743976
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo or sugar pill will be taken once daily for 6 weeks
Trial: NCT03518242
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT03518242
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT03518242
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01463228
Drug: A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
Trial: NCT01463228
Drug: B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
Trial: NCT01920503
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicina is loaded at the concentration of 50-75 mg/mq onto 2 ml of 70-150 µm M1 microspheres and is infused by TACE method
Trial: NCT00098254
Drug: BAY 43-9006 (Sorafenib)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self administered oral doses at 400 mg twice a day with 250 ml (8 oz.) of water each morning and evening (i.e., 12-hourly) continuously in a 28 day cycle. Tablets may be taken with or without food.
Trial: NCT02406989
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to MS-553
Trial: NCT00818064
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single s.c. injection (per dose cohort)
Trial: NCT04253119
Drug: Antiretroviral/Anti HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNRTI plus two NRTIs or PI boosted by ritonavir with 2 NRTIs per the usual standard of care of the investigator in AIDS clinics of Russia
Trial: NCT02165826
Drug: Standard of Care COPD Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participant is on standard of care COPD maintenance treatment including LABAs, long-acting anticholinergics, or any combination thereof taken on a constant daily dose within 12 weeks prior to Screening (Visit V0) Examples of LABA containing products are: Formoterol, Salmeterol, Indacaterol, Formoterol/Budesonide, Salmeterol/Fluticasone, Treatment including lon-acting anticholinergics: Tiotropium, Aclidinium.
Trial: NCT03421639
Drug: GnRH analog (11.25mg Leuprolide acetate)
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11.25 Leuprolide acetate only one administration
Trial: NCT03421639
Drug: Aromatase inhibitor and GnRH analog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg/day of Anastrazole for 3 months
Trial: NCT01002664
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 soft-gel placebo capsules Qd for 12 weeks
Trial: NCT03833895
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.05ug/kg/min Norepinephrine during Cesarean Section Operation
Trial: NCT02735837
Drug: placebo topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo topical gel was put into the periodontal pocket using an insulin syringe
Trial: NCT00445575
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
Trial: NCT00741715
Drug: AVE5530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration once daily in the evening with dinner
Trial: NCT00741715
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration once daily in the evening with dinner
Trial: NCT01071837
Drug: APG101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg weekly as intravenous infusion
Trial: NCT04585100
Drug: FM101 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio-equivalent test (tablet vs oral solution)
Trial: NCT04585100
Drug: FM101 oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio-equivalent test (tablet vs oral solution)
Trial: NCT04585100
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID for 28 days
Trial: NCT04585100
Drug: FM101 150 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FM101 (150 mg) BID for 28 days
Trial: NCT04585100
Drug: FM101 300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FM101 (300 mg) BID for 28 days
Trial: NCT00569192
Drug: 0.135mg MAP0010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
Trial: NCT00569192
Drug: 0.25mg MAP0010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
Trial: NCT00569192
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo delivered by nebulization twice daily for 12 weeks
Trial: NCT04072445
Drug: Trifluridine and Tipiracil Hydrochloride
RxNorm normalized name: tipiracil / trifluridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04568863
Drug: Melatonin intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day.
Trial: NCT04568863
Drug: Placebo intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours.
Trial: NCT04157036
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subject will take 800mg Ibuprofen 45 minutes prior to anesthetic delivery
Trial: NCT02270307
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose 50 mg/kg at day +3,+4 once daily
Trial: NCT00755456
Drug: PD solution containing glucose
RxNorm normalized name: calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal PD-2/2.5]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 120 days.
Trial: NCT00755456
Drug: PD solution containing glucose and L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 120 days.
Trial: NCT00730821
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00730821
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01507077
Drug: ZGN-440
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive ZGN-440 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
Trial: NCT01507077
Drug: ZGN-440 sterile diluent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
Trial: NCT00966264
Drug: LNG-IUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNG-IUS releasing 25 microg of levonorgestrel
Trial: NCT01090011
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBW 2992 medium dose plus high dose level of cetuximab
Trial: NCT01090011
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBW 2992 medium dose monotherapy, upon progression, cetuximab high dose is added
Trial: NCT04396847
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Tablet (BID)
Trial: NCT04597970
Drug: cTACE-HAIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transarterial chemoembolization (TACE) plus Hepatic Arterial Infusion Chemotherapy (HAIC) with oxaliplatin and raltitrexed for Barcelona stage C hepatocellular carcinoma (HCC)
Trial: NCT03455205
Drug: shenqifuzheng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500ml shenqifuzheng daily（at day 1-7and day22-28）through intravenous infusion.
Trial: NCT00671710
Drug: Aminolevulinic Acid
RxNorm normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escalating doses (10mg/kg, 20mg/kg, 30mg/kg) of Aminolevulinic Acid administered orally 3 hours prior to surgery to enhance visualization of malignant brain tumor.
Trial: NCT06119347
Drug: AntiVEGF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-vascular endothelial growth factor monoclonal antibody drug includes bevacizumab;
Trial: NCT03533777
Drug: To keep open (TKO) infusion of 0.9% normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After placement of the peripheral intravenous catheter, an infusion of 0.9% normal saline will be connected to the catheter and infused at a rate of 20 milliliters per hour to keep open (TKO) for future use by preventing blood clot development within the catheter.
Trial: NCT02660762
Drug: Intrathecal Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: induction therapy I：12.5 mg IT d15 induction therapy II：12.5 mg IT d1, 8, 15, 22
Trial: NCT02660762
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: induction therapy II:650 mg/m2 IV d1, 15, 29 consolidation therapy(Cycle 3)：650 mg/m2 IV，d29